Appointments: New CEO For Silence Therapeutics, Medical Heads Join Merck, Breath Therapeutics, Immusoft
David Solomon’s entrance as Silence Therapeutics’ new CEO leads this week’s new hires. While Ireland-based Malin shakes up its board of directors, other execs join Merck, Apeiron Biologics, Vectura, Roivant, OncoSec, Breath Therapeutics, Immusoft and M3 Biotechnology.
You may also be interested in...
Ferring Pharmaceuticals’ US CSO Elizabeth Garner talks to In Vivo about the future of fertility and where investment should be heading to make a dent in this multi-million-dollar market.
Mapping the patient journey uncovers a wealth of insights into care, diagnosis and intervention. The onset of advanced analytics tools and sensors now augment the pharma industry’s understanding of the challenges of traversing health care systems. Layering AI into the mapping process not only has the power to provide insights into the current clinical pathway, it can be used to predict and intervene in clinical care.
Despite decades of R&D, there are no disease modifying therapies on the market for Parkinson’s disease, and few efficacious products for non-motor symptoms. Clinical setbacks have been rife but breakthroughs in diagnostics and a better understanding of disease pathology brings hope for the future. In Vivo speaks to some of those responsible for bringing innovation to the field.